According to ENA Respiratory, California-based non-profit organization Flu Lab is providing a $5 million investment to support a Phase 2 proof of concept study of the company’s INNA-051 intranasal dry powder TLR2/6 agonist for the treatment of viral respiratory infections. The Phase 2 study will take place in the US and evaluate the safety and efficacy of INNA-051 for the prevention of infection by and treatment of symptoms caused by viruses such as flu, rhinovirus, coronavirus, and RSV in young adults.
In September 2024, ENA Respiratory announced additional funding for the development of INNA-051 from the US Department of Defense to support the addition of younger subjects to a Phase 1b study of INNA-051.
ENA Respiratory CEO Christophe Demaison commented, “There is an urgent need for new approaches to reduce the enormous burden of serious viral respiratory infections including influenza, and this investment from Flu Lab will allow us to accelerate our clinical program. We are delighted to have Flu Lab’s support and believe it is a strong endorsement of the work we have done to date in developing INNA-051 and its potential to make a meaningful difference in reducing mortality and morbidity.”
Read the ENA Respiratory press release
